RaQualia Pharma Inc. announced consolidated financial results for the nine months ended September 30, 2020. For the period, the company reported net sales of JPY 573 million against JPY 708 million a year ago. Operating loss was JPY 600 million against JPY 534 million a year ago. Loss attributable to owners of parent was JPY 698 million against JPY 531 million a year ago. Loss per share basic of JPY 33.35 against JPY 25.94 a year ago.